These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11929346)

  • 1. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use.
    Morris S; Anderson P; Irwin DE
    Pharmacoeconomics; 2002; 20(3):153-68. PubMed ID: 11929346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
    Grossman R; Mukherjee J; Vaughan D; Eastwood C; Cook R; LaForge J; Lampron N
    Chest; 1998 Jan; 113(1):131-41. PubMed ID: 9440580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
    Torrance G; Walker V; Grossman R; Mukherjee J; Vaughan D; La Forge J; Lampron N
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):499-520. PubMed ID: 10662396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
    Destache CJ; Dewan N; O'Donohue WJ; Campbell JC; Angelillo VA
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():107-13. PubMed ID: 10225580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?
    Obaji A; Sethi S
    Drugs Aging; 2001; 18(1):1-11. PubMed ID: 11232735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD.
    Miravitlles M; Murio C; Guerrero T; Gisbert R;
    Chest; 2002 May; 121(5):1449-55. PubMed ID: 12006427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
    Lipsky BA; Unowsky J; Zhang H; Townsend L; Talbot GH
    Clin Ther; 1999 Jun; 21(6):954-65. PubMed ID: 10440620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effective therapy for acute exacerbations of chronic bronchitis.
    Grossman RF
    Semin Respir Infect; 2000 Mar; 15(1):71-81. PubMed ID: 10749552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis.
    Pechère JC; Lacey L
    J Antimicrob Chemother; 2000 Mar; 45():19-24. PubMed ID: 10719008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis.
    Chodosh S
    Chest; 2005 Jun; 127(6):2231-6. PubMed ID: 15947342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease].
    Llor C; Naberan K; Cots JM; Molina J; Ros F; Miravitlles M;
    Arch Bronconeumol; 2006 Apr; 42(4):175-82. PubMed ID: 16735014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy.
    Saint S; Flaherty KR; Abrahamse P; Martinez FJ; Fendrick AM
    Clin Ther; 2001 Mar; 23(3):499-512. PubMed ID: 11318083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
    Schaberg T; Möller M; File T; Stauch K; Landen H
    Clin Drug Investig; 2006; 26(12):733-44. PubMed ID: 17274680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical contribution of the newer fluoroquinolones in acute bacterial exacerbation of chronic bronchitis].
    Niederman MS
    Medicina (B Aires); 1999; 59 Suppl 1():23-30. PubMed ID: 10436551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment cost of acute exacerbations of chronic bronchitis.
    Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
    Clin Ther; 1999 Mar; 21(3):576-91. PubMed ID: 10321424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
    Zuck P
    Presse Med; 2002 Jun; 31(21 Pt 2):S15-8. PubMed ID: 12148385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of gemifloxacin: results from the GLOBE study.
    Halpern MT; Palmer CS; Zodet M; Kirsch J
    Am J Health Syst Pharm; 2002 Jul; 59(14):1357-65. PubMed ID: 12132563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.